Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Campath-1H does not alter bone marrow cell regulatory function.

Yide Jin1, Laphalle Fuller, Anne Rosen

  • 1Lillian Jean Kaplan Renal Transplant Center of the Division of Transplantation of the Department of Surgery, at the University of Miami, Leonard M. Miller School of Medicine, Miami, FL 33101, USA. YJin@med.miami.edu

Human Immunology
|July 5, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ex Vivo Resection and Intestinal Autotransplantation: An International Multicenter Study.

Annals of surgery·2025
Same author

Uterus Transplantation: Revisiting the Question of Deceased Donors versus Living Donors for Organ Procurement.

Journal of clinical medicine·2022
Same author

Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2021
Same author

Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.

Artificial organs·2021
Same author

Polyphenols and Ischemic Stroke: Insight into One of the Best Strategies for Prevention and Treatment.

Nutrients·2021
Same author

Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting.

Journal of clinical medicine·2021

Alemtuzumab (C1H) treatment does not eliminate the immune-downregulating effects of bone marrow cells (BMC). This suggests C1H may enhance BMC

Area of Science:

  • Immunology
  • Transplantation immunology
  • Cellular immunology

Background:

  • Bone marrow cells (BMC) are known potent immunoregulators.
  • Alemtuzumab (C1H) is a potent T-cell depleting agent used in renal transplantation.
  • The combined effect of C1H and BMC on immune regulation is not fully understood.

Purpose of the Study:

  • To investigate whether C1H treatment affects the immunoregulatory capacity of BMC.
  • To compare the effects of C1H-treated and untreated BMC on T-cell responses in vitro.
  • To assess the potential for synergistic immunomodulation in kidney transplantation.

Main Methods:

  • Human T-cell depleted BMC (nT-BMC) were treated with C1H and rabbit complement or left untreated.
  • nT-BMC were co-cultured with autologous or allogeneic T cells.

Related Experiment Videos

  • Suppression of T-cell proliferation, cytotoxic function, and induction of T regulatory cells (Tregs) were measured.
  • Changes in CD3 signaling and adenosine triphosphate levels were analyzed.

    • Main Results:

    • C1H treatment did not abrogate the ability of BMC to suppress T-cell proliferation and cytotoxic function.
    • Both C1H-treated and untreated BMC equally induced CD4/CD25(high) T regulatory cells.
    • Co-culture with allogeneic C1H-treated nT-BMC resulted in significant suppression of T-cell cytotoxicity (85%) compared to untreated BMC (54%).

    Conclusions:

    • C1H does not eliminate the inherent immunoregulatory properties of BMC.
    • The lympho-depleting effect of C1H may be synergistic with the immunomodulatory effects of BMC.
    • These findings suggest a potential for enhanced immunotolerance in kidney allograft recipients.